# A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

> **NCT00482079** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 743 (actual)

## Conditions studied

- Diabetes Mellitus, Type II

## Interventions

- **DRUG:** MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks
- **DRUG:** Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks

## Key facts

- **NCT ID:** NCT00482079
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05-13
- **Primary completion:** 2004-08-25
- **Final completion:** 2006-06-15
- **Target enrollment:** 743 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00482079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00482079, "A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00482079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*